ORKA - Oruka Therapeutics, Inc.
44.48
-0.980 -2.203%
Share volume: 885,714
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$45.46
-0.98
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 04-25-2024 | 08-01-2024 | 11-13-2024 | 05-14-2025 | 08-11-2025 | 11-12-2025 | 03-12-2026 | |
| Assets | ||||||||
| Total Assets | 36.706 M | 33.844 M | 414.090 M | 377.112 M | 357.418 M | 509.251 M | 488.617 M | |
| Current Assets | 36.670 M | 33.820 M | 412.949 M | 352.083 M | 332.012 M | 355.163 M | 343.857 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 767.000 K | 537.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 265.522 M | 263.010 M | 257.902 M | 290.109 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 35.903 M | 33.283 M | 410.875 M | 83.572 M | 65.396 M | 91.253 M | 46.935 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 23.953 M | 23.053 M | 151.763 M | 142.539 M | |
| Property Plant Equipment | 7.000 K | 4.000 K | 160.000 K | 159.000 K | 174.000 K | 253.000 K | 288.000 K | |
| Other Assets | 29.000 K | 20.000 K | 981.000 K | 24.870 M | 25.232 M | 153.835 M | 144.472 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 36.706 M | 33.844 M | 414.090 M | 377.112 M | 357.418 M | 509.251 M | 488.617 M | |
| Total liabilities | 1.581 M | 1.271 M | 18.881 M | 12.387 M | 13.776 M | 22.460 M | 16.687 M | |
| Total current liabilities | 1.581 M | 1.271 M | 18.039 M | 11.723 M | 12.110 M | 20.967 M | 15.374 M | |
| Accounts Payable | 529.000 K | 571.000 K | 0.000 | 4.362 M | 4.783 M | 2.216 M | 4.164 M | |
| Other liabilities | 0.000 | 0.000 | 842.000 K | 664.000 K | 1.666 M | 1.493 M | 1.313 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 842.000 K | 664.000 K | 1.666 M | 1.493 M | 1.313 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 35.125 M | 32.573 M | 339.437 M | 361.794 M | 340.711 M | 483.860 M | 468.999 M | |
| Common stock | 225.875 M | 226.001 M | 397.380 M | 466.523 M | 470.035 M | 643.249 M | 657.610 M | |
| Retained earnings | -190.750 M | -193.428 M | -57.943 M | -104.723 M | -129.297 M | -159.574 M | -189.157 M |